ABSTRACT: We previously reported that perlecan, a heparan-sulfate proteoglycan (Hspg2), expressed in the synovium at the cartilagesynovial junction, is required for osteophyte formation in knee osteoarthritis. To examine the mechanism underlying this process, we examined the role of perlecan in the proliferation and differentiation of synovial mesenchymal cells (SMCs), using a recently established mouse synovial cell culture method. Primary SMCs isolated from Hspg2
Osteoarthritis (OA) is a disease characterized primarily by cartilage degradation as the hallmark, 1 whereas synovitis and osteophyte formation have been considered as secondary phenomena. 2 Osteophytes are a bony outgrowths at the joint margins that originate primarily from the periosteum covering the bone at the cartilage bone junction, but cell populations from the synovium, which covers the periosteum may also participate in osteophyte formation. 3 Synovial mesenchymal cells (SMCs) are stimulated to proliferate by various triggers, such as mechanical factors and cytokines and can be triggered to form cartilage. 3 The cells inside the developing osteophyte undergo chondrogenesis and differentiate into mature hypertrophic chondrocytes in the areas where vascular invasion occurs. The mature hypertrophic chondrocytes are subsequently replaced with osteoblasts to form bone with marrow cavities. These developmental processes in the osteophyte are similar to those seen during endochondral ossification in the growth plate. [3] [4] [5] [6] [7] [8] Perlecan (Hspg2) is a heparan sulfate proteoglycan present in all basement membranes, as well as in cartilage and the synovium. [9] [10] [11] [12] Perlecan interacts with extracellular matrix molecules, receptors, and growth factors and is implicated in cell growth, differentiation, signaling, and stem cell maintenance. 13, 14 Perlecan is essential for cartilage development, and perlecan-deficient mice and humans develop dwarfism with short limbs and defective cartilage and die at birth. 4, 9, 15 To investigate the role of perlecan expressing other than cartilage, we created mice in which the transgenic perlecan was expressed specifically in chondrocytes by introducing the transgene (Hspg2-Tg) under the control of a cartilage-specific Col2a1 promoter and enhancer in the Hspg2 À/À genetic background (Hspg2 À/À -Tg). 4, 9, 16, 17 The Hspg2
-Tg mice survived, and their bone sizes were similar to those of wild-type mice. 4 
In these Hspg2
À/À -Tg mice, perlecan is expressed in cartilage but absent in the basement membranes of blood vessels, 4 muscle, 17 heart, brain, and other tissues surrounding cartilage, including synovium. 19 Histological analysis showed that the columnar structure of the growth plate is restored in Hspg2 À/À -Tg mice. Type II collagen, type X collagen, and osteopontin were expressed in cartilage of Hspg2 À/À -Tg mice similar to those of wild-type mice. Vascular invasion into the chondro-osseous region observed in the Hspg2 À/À -Tg mice was occurred similar to that of wild-type mice. 4 
Although Hspg2
À/À -Tg mice can survive and fertile, it has been reported that perlecan plays an important role in development and homeostasis of certain organs using Hspg2
À/À -Tg mice. 17, 18, 20 For example, perlecan deficiency causes muscle hypertrophy, changes in muscle fiber composition, and a decrease in myostatin expression. 17 Perlecan deficiency also causes endothelial dysfunction, a key variable in the pathogenesis of atherosclerosis, by reducing the expression of endothelial perlecan. 20 Perlecan deficiency reduces the number of both GFAP/CD133-positive neural stem cells in the subventricular zone and new neurons integrating into the olfactory bulb. 18 These studies suggest that perlecan is a component of the neurogenic niche that regulates FGF-2 signaling and acts by promoting neural stem cell self-renewal and neurogenesis. 18 Thus, the Hspg2 À/À -Tg mouse line is useful mouse model to study the role of perlecan in tissue homeostasis and diseases. We have previously shown that synovial perlecan is required for osteophyte formation in OA using a mouse (Hspg2 À/À -Tg) model. 19 However, it has remained unclear why synovial perlecan is required for osteophyte formation, and how it contributes to the differentiation of SMCs in the synovium.
Based on this previous knowledge, we hypothesized that synovial perlecan plays an important role in the chondrogenic differentiation of SMCs. The purpose of the present in vitro study was to determine the role of perlecan in the chondrogenic differentiation of SMCs.
METHODS

Mice
We used Hspg2
;Col2a1-Hspg2 Tg/À ) mouse. 4, 9, 16, 17 Ten-week-old female adult Hspg2 À/À -Tg mice and wild-type Hspg2
Tg/À ) control littermates were used for the experiments. 4, 17, 19 All experimental procedures were performed following the guidelines for the care and use of animals, and received institutional ethical approval from the animal ethics committee (Registration Number: 971, Permit Number: 230017, 240023, 250167, and 2601014).
SMC Isolation
The synovial tissues were dissected from the knee joint of Hspg2 À/À -Tg and control Hspg2 þ/þ -Tg mice, and primary SMCs were isolated as described previously. 21 Nucleated cells were plated in six-well dishes for 24 h in complete culture medium (DMEM containing 20% [v/v] fetal bovine serum [FBS] , 100 units/ml penicillin, and 100 mg/ml streptomycin [Invitrogen, Carlsbad, CA]) and were incubated at 37˚C with 5% (v/v) humidified CO 2 . The medium was changed every 2-3 days thereafter, and the cells were cultured for 14 days as passage 0.
Cell Expansion Assay
To analyze the cell growth kinetics, we plated passage 4 SMCs at 1,000 cells/cm 2 and cultured them for 14 days, counting the number of cells every 2 days. In addition, the bromodeoxyuridine (BrdU) colorimetric ELISA kit (Roche, Indianapolis, IN) was used to assess the proliferation of control-and Hspg2 À/À -Tg SMCs. Briefly, the passage 2 SMCs were seeded in duplicate at 1,000 cells/well into 96-well plates, and incubated at 37˚C with 5% (v/v) humidified CO 2 for 5 days. The proliferation rates of the cells were calculated based on the measurement of BrdU incorporation during DNA synthesis. The extent of cell proliferation was measured by assessing the absorbance at 370-392 nm.
Flow Cytometry
The fluorescence-activated cell sorting (FACS) flow cytometry analyses were performed following the previously reported method. 21 The details of the antibodies used for FACS are shown in Supplemental Table S1 . Cell fluorescence was evaluated by FACS using a FACSAria instrument (Becton Dickinson, Franklin Lakes, NJ) and the data were analyzed using the CellQuest software program (Becton Dickinson).
In Vitro Chondrogenesis A total of 2.0 Â 10 6 cells in passage 4 were centrifuged to obtain a density of 5.0 Â 10 5 cells/10 ml. The cell suspensions (10 ml) were then placed in 24-well plates (Corning, NY) at the center of each well for 2-3 h until attached and the micromass left resting for further 24 h with culture medium before adding chondrogenic differentiation medium. Chondrogenic differentiation medium consisted of maintenance supplemented with 10 ng/ml TGF-b3 (R&D Systems, Minneapolis, MN), 100 nM dexamethasone, 50 mg/ml ascorbate-2-phosphate (Sigma-Aldrich, Missouri, SL), 40 mg/ml proline (Sigma-Aldrich), 100 mg/ml pyruvate (Sigma-Aldrich), and 1:100 diluted ITS þ Premix (Becton Dickinson), 22 which allowed cells to form three-dimensional (3D) micromass cultures. 23 The micromasses were cultured at 37˚C with 5% (v/v) humidified CO 2 in 1 ml of chondrogenic medium. The medium was replaced every other day for 3 days.
To evaluate the chondrogenic potential of the SMCs in micromass cultures, we measured expression levels of chondrogenic markers, sex-determining region Y-box 9 (Sox9), Sox5, and type II collagen alpha 1 (Col2a1) quantitative realtime polymerase chain reaction (qRT-PCR) at 3, 12, and 72 h after chondrogenic induction. For perlecan rescue experiments, 0.1, 1, and 10 mg/ml of exogenous perlecan (Heparin sulfate proteoglycan: HSPG, Cat# H4777, isolated from the basement membrane of Engelbreth-Holm-Swarm [EHS] mouse sarcoma, Sigma-Aldrich) were added to both the micromass, high density cell suspensions (10 ml) and the chondrogenic culture medium. The sex-determining region Sox9 mRNA levels were evaluated by qRT-PCR at 3 h after chondrogenic induction. The heparan sulfate chains of perlecan (EHS-HSPG) were digested by heparinase, as the previous reports with some modifications. 13, 20 The 5 mg of the EHS-HSPG were incubated with 5 mU/ml of heparinase (Heparinas III, Cat# H8891, Sigma-Aldrich) in 50 mM Tris-HCL (pH 7.0), containing 3 mM NaCl, and 10 mM CaCl 2 at 37˚C for 24 h. After incubation, the heparinase solution was removed by filtration (Amicon Ultra centrifugal filters,
Millipore, Darmstadt, Germany). We confirmed successful heparinase digestion of perlacan by reactivity of the antibody 3G10, which recognizes heparin sulfate neo-epitope 3G10 using Western blotting.
In Vitro Osteogenesis and Adipogenesis
The osteogenic potential of the SMCs was evaluated by Alizarin red staining followed by the colony forming assay (CFU) for 21 days, and via qRT-PCR analysis at 3 h after osteogenic induction, as previously described. 21 Briefly, 1,000 cells were plated in 60-cm 2 dishes and cultured in complete DMEM medium for 7 days. The medium was then switched to osteogenic medium that consisted of the complete DMEM medium supplemented with 1 nM dexamethasone (Sigma-Aldrich), 20 mM glycerol phosphate (Sigma-Aldrich), and 50 mg/ml ascorbate-2-phosphate (Sigma-Aldrich) for an additional 21 days. The osteogenic medium was replaced every 2-3 days. The dishes were subsequently stained with 0.5% (w/v) alizarin red solution, and the number of alizarin red-positive colonies was determined. Colonies less than 2 mm in diameter and faintly stained colonies were ignored. The same calcification cultures were then stained with crystal violet, and the total number of cell colonies was determined. 21 The adipogenic potential of the SMCs was evaluated by Oil-red O staining 21 days after adipogenic induction, and qRT-PCR at 3 h after adipogenic induction, as described. 21 Briefly, after culturing cells in complete medium for 7 days, the medium was then switched to the adipogenic medium that consisted of complete medium supplemented with 10 nM dexamethasone, 0.5 mM isobutylmethylxanthine (SigmaAldrich), and 50 mM indomethacin (Sigma-Aldrich) for an additional 21 days. The adipogenic medium was replaced every 2-3 days. The adipogenic cultures were fixed in 4% (w/v) paraformaldehyde, stained with 0.5% (w/v) Oil-red O solution, and the number of Oil-red O-positive colonies was determined. 21 In the perlecan rescue experiment, 0.01, 0.1, 1, and 10 mg/ml of EHS-HSPG were added to the adipogenic culture medium, and the peroxisome proliferator-activated receptor g (PPARg) gene expression was evaluated by qRT-PCR at 3 h after adipogenic induction.
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) Total RNA from cultured cells was prepared using the Absolutely RNA Nanoprep Kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized using the Transcriptor High Fidelity cDNA Synthesis Kit (Roche Applied Science, Mannheim, Germany) using random hexamer primer.
The qRT-PCR analyses were performed with an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA) using SYBR Green I PCR reagents (TOYOBO, Osaka, Japan) under the following conditions: Initial denaturation for 10 min at 94˚C followed by 40 cycles consisting of 15 s at 94˚C and 1 min at 60˚C. The copy number was expressed as the number of transcripts per nanogram of total RNA. Experimental samples were matched to a standard curve generated by amplifying serially diluted products using the same PCR protocol. The amounts of mRNA are shown as relative quantities in comparison to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA.
For the qRT-PCR analyses, primers for the following target genes were used (Supplemental Table S2 ): Sox9, Sox5, and Col2a1 for chondrogenesis; runt-related transcription factor 2 (Runx2), type I collagen alpha 1 (Col1a1), osteocalcin and alkaline phosphatase (ALP) for osteogenesis; PPARg and fatty acid binding protein 4 (FABP4) for adipogenesis.
Western Blotting
The protein concentration was determined using a BCA protein assay kit (Thermo Scientific, Rockford, IL) and then solubilized in LDS sample buffer (Life Technologies, Carlsbad, CA) containing dithiothreitol. The samples (10 mg/lane) were resolved by electrophoresis on 3-8% (w/v) Tris-Acetate SDS-PAGE gels, and then transferred to a PVDF membrane (Life Technologies). After blocking with PVDF blocking reagent (TOYOBO), the membrane was incubated with primary antibodies in Tris-buffered saline with tween 20 (TBS-T) overnight. After washing, the membrane was incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies in TBS-T and visualized with SuperSignal West Dura Extended Duration Substrate (Thermo Scientific). The antibodies were prepared as follows: The primary antibodies, anti-heparan sulfate antibody (10E4, Seikagaku Corporation, Tokyo, Japan), anti-D-heparan sulfate antibody (3G10, Seikagaku Corporation, Tokyo, Japan) and antiperlecan domain V antibody (from Dr. Sasaki) were diluted at 1:1,000, 1:500, and 1:1,000, respectively, in TBS-T. The second anti-mouse IgM HRP-conjugated secondary antibodies (abcam, Cambridge, UK), anti-mouse IgG HRP-conjugated secondary antibodies (GE Healthcare, Little Chalfont, UK) and anti-rabbit HRP-conjugated secondary antibodies (GE Healthcare) were diluted at 1:5,000 in TBS-T.
Statistical Analysis
An unpaired t-test was used to assess the significance of differences. The multiple comparisons were conducted an analysis of variance (ANOVA). Values of p < 0.05 were considered to be significant.
RESULT Perlecan Is Not Expressed in Primary SMCs From Hspg2
À/À -Tg Mice Hspg2 À/À -Tg mice display normal survival rate and cartilage development, but the perlecan transgene is not expressed in the synovium. We isolated SMCs from the synovium of the knee joints of wild-type control and Hspg2 À/À -Tg mice, respectively, using our previously published method. 21 Similar to the in vivo situation, and in agreement with our previous reports using Hspg2
À/À -Tg mice, 19 the Hspg2 À/À -Tg SMCs isolated from Hspg2 À/À -Tg mice did not express perlecan while control SMCs from Hspg2 þ/þ -Tg did, as assessed by both qRT-PCR (Fig. 1A) and immunohistochemical analyses (Fig. 1B) . These results showing the lack of expression of perlecan in SMCs from Hspg2 À/À -Tg mice reflect the successful cartilagespecific rescue of perlecan expression that we had observed in vivo in those mice. Fig. 2A) . The proliferative potential, measured by BrdU incorporation analysis, also showed no significant difference between control and Hspg2 À/À -Tg SMCs (Fig. 2B ).
Control and Hspg2
À (Fig. 3) .
Reduced Chondrogenic Potential in Micromass Cultures of Hspg2
À/À -Tg SMCs Next, we examined the chondrogenic potential of control and Hspg2 À/À -Tg SMCs in micromass cultures. Type II collagen immunostaining was intense in micromasses of control SMCs during in vitro chondrogenesis (Fig. 4A) , but was dramatically reduced in the micromass cultures of Hspg2 À/À -Tg SMCs (Fig. 4A) . Accordingly, qRT-PCR analysis demonstrated that Sox9 mRNA was expressed in the control SMCs 3, 12, and 72 h after the initiation of the micromass culture (Fig. 4B) , and that the Sox9 expression levels were significantly reduced in the micromass cultures of Hspg2 À/À -Tg SMCs (Fig. 4B) . Further, we also detected lower Sox5 mRNA expression in micromasses of Hspg2 À/À -Tg SMCs at 3, 12, and 72 h from the initiation of the micromass culture, compared to controls SMCs (Fig. 4B) . While the Sox5 mRNA in control SMCs increased, there was no such increase in the micromasses of Hspg2 À/À -Tg SMCs. The Sox5 mRNA levels were significantly reduced in the micromass cultures of Hspg2 À/À -Tg SMCs at 12 and 72 h (Fig. 4B) .
Finally, Col2a1 mRNA was also detected at 3, 12, and 72 h after the initiation of the micromass cultures of control SMCs (Fig. 4B) , but was reduced in micromasses of Hspg2 À/À -Tg SMCs (Fig. 4B) . Together, these results clearly indicate that Hspg2 À/À -Tg SMCs display a less efficient chondrogenic potential in vitro.
To confirm the direct involvement of perlecan in the chondrogenic potential of SMCs, we supplemented the in vitro cultures with purified perlecan (EHS-HSPG) to rescue Hspg2 À/À -Tg SMCs from perlecan deficiency. The EHS-HSPG contains perlecan protein (Fig. 4C) , and the Sox9 expression was dose-dependently restored by the addition of EHS-HSPG to the chondrogenic medium (Fig. 4D) . To examine the involvement of the heparin-sulfate side chains covalently bound to perlecan or the perlecan core protein without the heparin-sulfate side chains in this process, the heparin sulfate side chains were released from perlacan by heparinase digestion. The heparin sulfate binging sites of the perlecan core protein were confirmed to be free after the digestion by the antibody 3G10, which recognizes the heparin sulfate neo-epitope 3G10 (Fig. 4E) . The perlecan core protein was able to restore the Sox9 expression, as it was added to the chondrogenic medium (Fig. 4F) . These results suggest a direct link between perlecan and the chondrogenic potential of SMCs.
SMCs Have Similar Osteogenic Potentials Regardless of the Presence or Absence of Perlecan
Next, we examined whether perlecan is involved in the osteogenic potential of SMCs. We observed the Alizarin red-positive CFUs following the osteogenic induction in the cultures of both control and Hspg2 À/À -Tg SMCs (Fig. 5A) . The number of Alizarin red-positive CFU in the cultures of Hspg2 À/À -Tg SMCs was similar to that in the control SMCs (Fig. 5B) . During in vitro osteogenic induction, the mRNA levels of the osteogenic markers, Runx2, Col1a1, osteocalcin, and ALP were equivalent in cultures of control and Hspg2 À/À -Tg SMCs, and no significant difference was observed by qRT-PCR (Fig. 5C ).
Impaired Adipogenesis in SMC Cultures in the Absence of Perlecan
We further examined whether perlecan is involved in the adipogenic potential of SMCs. Following adipogenic induction, we observed Oil-red O-positive CFUs in the cultures of control SMCs (Fig. 6A) . While Oilred O-positive CFUs were also detected in cultures of Hspg2 À/À -Tg SMCs, the number of positively stained cells was significantly reduced compared to control SMCs (Fig. 6B) .
Accordingly, the levels of PPARg and FABP4 mRNA were also significantly reduced in the cultures of Hspg2 À/À -Tg SMCs compared to control SMCs during in vitro adipogenesis (Fig. 6C) . Importantly, the addition of the perlecan protein (EHS-HSPG) to the adipogenic medium in Hspg2 À/À -Tg SMCs cultures restored the expression of PPARg, a key transcription factors for adipogenesis, in a dose-dependent manner (Fig. 6D) , suggesting that perlecan is directly involved in the adipogenic potential of SMCs.
DISCUSSION
In this in vitro study, we showed that perlecan in the synovial niche is required for the chondrogenic and adipogenic, but not osteogenic, differentiation of SMCs. The contribution of perlecan to chondrogenesis in SMCs supports the notion that these cells constitute a source of cells for cartilage tissue engineering approaches. [21] [22] [23] Our in vitro results are also consistent with our previous report using animal models that perlecan plays an important role in osteophyte formation in knee OA, 19 but suggests that it supports the endochondral phase requiring chondrogenesis.
The osteophyte formation in OA occurs through a series of highly coordinated biological processes that include proliferation and differentiation of mesenchymal cells of the periosteum and synovium, the deposition and remodeling of the cartilage matrix, vascular invasion, mineralization, and bone marrow formation. SMCs in the synovium are stimulated to proliferate by various triggers, such as mechanical factors and synovitis. 3 It remains unclear whether synovitis is involved in osteophyte formation, however, less osteophyte formation is observed in patients with rheumatoid arthritis, where synovial inflammation plays a crucial role. 24 In our previous study, the histological synovitis in the Hspg2 À/À -Tg OA mice was similar to that in the control mice, 19 suggesting that synovial perlecan may affect osteophyte formation independent of the development of OA. As osteophyte formation in the absence of perlecan was inhibited from the early stage of knee OA in vivo, 19 synovial perlecan may be involved in a relatively early phase of this process, such as SMC proliferation and differentiation. We therefore believed that an in vitro study using SMCs would be helpful to provide insight into the role of perlecan in osteophyte formation as a rationale for performing these experiments.
SMCs from Hspg2
À/À -Tg mice lack perlecan, but were viable and proliferative in culture similar to control SMCs. However, in chondrogenic media, the expression of Sox9 mRNA was higher in control SMCs than in Hspg2 À/À -Tg SMCs. This reduced Sox9 mRNA levels in Hspg2 À/À -Tg SMCs were restored abrogated by the supplementation with perlecan protein in micromass cultures (Fig. 4) , indicating a direct involvement of perlecan in chondrogenesis. Since perlecan is located in the pericellular regions and modulates signaling molecules, such as fibroblast growth factors (FGFs), bone morphogenetic proteins (BMPs), transforming growth factor beta (TGF-b), and vascular endothelial growth factor (VEGFs), 4, 18, 19 we speculate that perlecan in the synovium is permissive for chondrogenic differentiation of SMCs via regulation of Sox9 expression without modulation of cellular signaling required for osteogenesis.
Perlecan has been implicated in cell growth, differentiation, signaling, and stem cell maintenance under both physiological and pathological conditions. 25, 26 During growth plate development in mice and humans, perlecan is required not only for differentiation but also for the proliferation of chondrocytes, which is regulated by FGF-2.
9,27,28 Perlecan also plays an important role in the vascular invasion into cartilage via the regulation of VEGF signaling in endothelial cells during growth plate development. 4 Perlecan is a component of the neurogenic niche, where it regulates FGF-2 signaling and promotes neural stem cell self-renewal and neurogenesis. 18 While synovial perlecan is involved in osteophyte formation, which is regulated, at least in parts, by TGF-b in the knee OA model, 19 BMPs, FGF2, and insulin-like growth factor 1 (IGF-1) are also implicated in osteophyte formation. [29] [30] [31] [32] In addition, the perlecan domain I synergizes with exogenous BMP2 to facilitate chondrogenesis of C3H10T1/2 mesenchymal cells. 33 The GAG-bearing domain I of perlecan provides a sufficient signal to trigger C3H10T1/2 cells to enter a chondrogenic differentiation pathway. 34 The differences of the role of the perlecan core protein between the previous and present studies may be due to the differences in cell sources, the mouse embryonic fibroblastic C3H10T1/2 mesenchymal cell line and primary mouse synovial mesenchymal cells. Although we added TGF-b, no other cytokine, such as BMPs, FGF2, or IGF-1, was added as a supplement in the in vitro chondrogenesis medium in the present study.
The results of the present study suggests a direct link between perlecan and the chondrogenic potential of SMCs (Fig. 4) . Perlecan, a heparan sulfate proteoglycan (HSPG), in the developing growth plate contains both HS and chondroitin sulfate (CS) chains. 35 The CS chains are suggested to modulate the binding of ligand to the receptor. 35 Perlecan in the growth plate binds to FGF-2 through its HS chains but can only deliver FGF-2 to FGF receptors when its CS chains are removed by digesting with chondroitinase ABC. While the previous study examined the role of the perlecan in growth plate, we examined the role of the perlecan in synovium. We have examined whether CS chains are expressed in EHS-HSPG by Western blot. We have observed that CS expression was not detectable by Western blot (data not shown). Although it is still unclear whether perlecan in the synovium contains CS chains, in addition to HS chains, our study showed the direct link between synovial perlecan and the chondrogenic potentials of SMCs.
PPARg and the CCAAT/enhancer binding protein alpha (C/EBPa) are induced during adipogenesis and regulate adipocyte differentiation. 36 Cross-regulation of PPARg and C/EBPa are involved in the induction of the two factors during adipogenic processes. 37 For example, PPARg binds to the promoter region of the C/EBPa gene to activate the C/EBPa transcription. 38 We found that the expression level of PPARg was very low in Hspg2 À/À -Tg SMCs cultured in the adipogenic induction media (Fig. 6C ). This failure of the PPARg induction in the absence of perlecan accounts, at least in part, for the defects in the adipogenic potential of 
Hspg2
À/À -Tg SMCs, since the addition of exogenous perlecan to the media restored the PPARg induction in Hspg2 À/À -Tg SMCs (Fig. 6D) . These results indicate the direct link between perlecan and PPARg expression in adipogenesis.
In contrast to the positive role of perlecan in chondrogenesis and adipogenesis of SMCs, perlecan deficiency did not affect osteogenic potential of SMCs.
À/À -Tg SMCs showed Alizarin red staining with similar levels to that of control SMCs at 21 days with the osteogenic media ( Fig. 5A and B ). There were also no significant differences in osteogenic marker expression levels between the control and Hspg2 À/À -Tg SMCs at 3 h after the osteogenic induction (Fig. 5C) .
We showed in the present study that perlecan was required for the chondrogenic and adipogenic differentiation from SMCs via its regulation of the Sox9 and PPARg gene expression, but not for osteogenic differentiation via Runx2. One possible explanation for these differential effects of perlecan may be that perlecan promotes selective signaling pathways necessary for differentiation to specific cell types. However, only female mice were used in the present study, as female mice were used in our previous study 19 because osteoarthritis is a female-dominant disease. This study was conducted to further examine the role of synovial perlecan to extend previous study. 19 It has been reported that there are sex differences in the mesenchymal cell differentiation potential. 39, 40 Therefore, different gender effects of perlecan on chondrogenic, adipogenic, and osteogenic potentials may occur. Our findings provide new selective bioengineering approaches using SMCs useful for cartilage tissue engineering where ossification is not desirable. 
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